J Med Assoc Thai 2013; 96 (11):1416

Views: 1,198 | Downloads: 43 | Responses: 0

PDF XML Respond to this article Print Alert & updates Request permissions Email to a friend

CHOEP-21 Chemotherapy for Newly Diagnosed Nodal Peripheral T-Cell Lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital
Rattarittamrong E Mail, Norasetthada L , Tantiworawit A , Chai-Adisaksopha C , Nawarawong W

Objective: To determine the effectiveness and tolerability of the combination of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with the addition of etoposide (CHOEP-21) for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs).

Material and Method: Between January 2009 and October 2011, patients aged 18 to 60 years with newly diagnosed nodal PTCLs at the Maharaj Nakorn Chiang Mai Hospital were enrolled to receive CHOEP-21 every three weeks for eight cycles. G-CSF prophylaxis was given to all patients.

Results: Twenty-four patients were enrolled. Twenty of them were male with a median age of 49 years. The majority of patients (66.7%) had PTCL, not otherwise specified (PTCL, NOS), and 95.8% of the patients were in stage III or IV. The overall response rate was 58% with 42% having complete response. The response rates were better among patients with ALK-negative anaplastic large cell lymphoma (ALCL; 100%) and angioimmunoblastic T-cell lymphoma (AITL; 85%) than those with PTCL, NOS (44%). With a median follow-up of 21 months, the patients had an estimated 2-year event-free survival, and an overall survival rate of 37.6% and 54.4%, respectively. The most common adverse effects were infection and hematologic toxicities that was manageable.

Conclusion: Although CHOEP-21 induced favorable responses in patients with ALK-negative ALCL and AITL, the responses were not durable and further therapy is mandated in management of patients with nodal PTCL.

Keywords: T-cell lymphomas, CHOEP-21 chemotherapy

Download: PDF